DIM affects how the liver processes estrogen that has already been used: it shifts the mix of estrogen breakdown products toward the milder 2-hydroxyestrone. In a 12-month trial in women taking tamoxifen, that ratio did rise, but breast density did not change; and the active metabolites of tamoxifen were lower in the DIM group, and whether that weakens the drug is not known.